408 related articles for article (PubMed ID: 33306126)
1. BCL7C suppresses ovarian cancer growth by inactivating mutant p53.
Huang C; Hao Q; Shi G; Zhou X; Zhang Y
J Mol Cell Biol; 2021 May; 13(2):141-150. PubMed ID: 33306126
[TBL] [Abstract][Full Text] [Related]
2. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
3. Plakoglobin Reduces the in vitro Growth, Migration and Invasion of Ovarian Cancer Cells Expressing N-Cadherin and Mutant p53.
Alaee M; Danesh G; Pasdar M
PLoS One; 2016; 11(5):e0154323. PubMed ID: 27144941
[TBL] [Abstract][Full Text] [Related]
4. CCDC106 promotes the proliferation and invasion of ovarian cancer cells by suppressing p21 transcription through a p53-independent pathway.
Zhao N; Wang C; Guo P; Hou J; Yang H; Lan T; Zhou Y; Li J; Bhawal UK; Liu Y
Bioengineered; 2022 Apr; 13(4):10956-10972. PubMed ID: 35484984
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-1β promotes ovarian tumorigenesis through a p53/NF-κB-mediated inflammatory response in stromal fibroblasts.
Schauer IG; Zhang J; Xing Z; Guo X; Mercado-Uribe I; Sood AK; Huang P; Liu J
Neoplasia; 2013 Apr; 15(4):409-20. PubMed ID: 23555186
[TBL] [Abstract][Full Text] [Related]
6. p53 and ANXA4/NF‑κB p50 complexes regulate cell proliferation, apoptosis and tumor progression in ovarian clear cell carcinoma.
Liu J; Wang H; Zheng M; Deng L; Zhang X; Lin B
Int J Mol Med; 2020 Dec; 46(6):2102-2114. PubMed ID: 33125094
[TBL] [Abstract][Full Text] [Related]
7. The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.
Yuan Z; Cao K; Lin C; Li L; Liu HY; Zhao XY; Liu L; Deng HX; Li J; Nie CL; Wei YQ
Mol Med; 2011; 17(11-12):1262-74. PubMed ID: 21863213
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of fibronectin following loss of p53 function is a poor prognostic factor in ovarian carcinoma with a unique immunophenotype.
Yokoi A; Matsumoto T; Oguri Y; Hasegawa Y; Tochimoto M; Nakagawa M; Saegusa M
Cell Commun Signal; 2020 Jul; 18(1):103. PubMed ID: 32635925
[TBL] [Abstract][Full Text] [Related]
9. PRL-3 suppresses c-Fos and integrin α2 expression in ovarian cancer cells.
Liu H; Al-aidaroos AQ; Wang H; Guo K; Li J; Zhang HF; Zeng Q
BMC Cancer; 2013 Feb; 13():80. PubMed ID: 23418787
[TBL] [Abstract][Full Text] [Related]
10. Pleckstrin homology domain-containing protein PHLDB3 supports cancer growth via a negative feedback loop involving p53.
Chao T; Zhou X; Cao B; Liao P; Liu H; Chen Y; Park HW; Zeng SX; Lu H
Nat Commun; 2016 Dec; 7():13755. PubMed ID: 28008906
[TBL] [Abstract][Full Text] [Related]
11. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
12. Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase/cGMP pathway in human ovarian cancer cells.
Fraser M; Chan SL; Chan SS; Fiscus RR; Tsang BK
Oncogene; 2006 Apr; 25(15):2203-12. PubMed ID: 16288207
[TBL] [Abstract][Full Text] [Related]
13. Mutation or loss of p53 differentially modifies TGFβ action in ovarian cancer.
Ó hAinmhire E; Quartuccio SM; Cheng W; Ahmed RA; King SM; Burdette JE
PLoS One; 2014; 9(2):e89553. PubMed ID: 24586866
[TBL] [Abstract][Full Text] [Related]
14. Ubiquitin ligase TRIM71 suppresses ovarian tumorigenesis by degrading mutant p53.
Chen Y; Hao Q; Wang J; Li J; Huang C; Zhang Y; Wu X; Lu H; Zhou X
Cell Death Dis; 2019 Sep; 10(10):737. PubMed ID: 31570706
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53.
Lu P; Vander Mause ER; Redd Bowman KE; Brown SM; Ahne L; Lim CS
J Ovarian Res; 2019 May; 12(1):45. PubMed ID: 31092272
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Ovarian Epithelial Carcinoma Tumorigenesis and Progression by microRNA 106b Mediated through the RhoC Pathway.
Chen S; Chen X; Xiu YL; Sun KX; Zhao Y
PLoS One; 2015; 10(5):e0125714. PubMed ID: 25933027
[TBL] [Abstract][Full Text] [Related]
17. ZCCHC10 suppresses lung cancer progression and cisplatin resistance by attenuating MDM2-mediated p53 ubiquitination and degradation.
Ning Y; Hui N; Qing B; Zhuo Y; Sun W; Du Y; Liu S; Liu K; Zhou J
Cell Death Dis; 2019 May; 10(6):414. PubMed ID: 31138778
[TBL] [Abstract][Full Text] [Related]
18. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
19. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo.
Concin N; Becker K; Slade N; Erster S; Mueller-Holzner E; Ulmer H; Daxenbichler G; Zeimet A; Zeillinger R; Marth C; Moll UM
Cancer Res; 2004 Apr; 64(7):2449-60. PubMed ID: 15059898
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer.
Chen X; Dong C; Law PT; Chan MT; Su Z; Wang S; Wu WK; Xu H
Gynecol Oncol; 2015 Dec; 139(3):513-9. PubMed ID: 26472353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
